仙琚制药(002332) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 1,037,926,735.62, representing an increase of 8.42% compared to CNY 957,286,011.96 in the same period last year[5] - Net profit attributable to shareholders was CNY 151,121,862.92, up 13.53% from CNY 133,111,920.61 year-on-year[5] - Net profit for Q1 2024 was ¥156,516,313.26, representing a 21.0% increase from ¥129,297,563.51 in Q1 2023[19] - Basic and diluted earnings per share were both ¥0.15, compared to ¥0.13 in the previous year[20] - The company reported a total comprehensive income of ¥126,343,444.31, down from ¥143,736,260.16 in the same period last year[20] Cash Flow - The net cash flow from operating activities increased by 57.63%, reaching CNY 109,025,001.56 compared to CNY 69,164,061.26 in the previous year[5] - Cash inflow from operating activities totaled ¥825,567,894.71, an increase from ¥787,694,437.80 in the same quarter last year[21] - The net cash flow from operating activities for Q1 2024 was ¥109,025,001.56, an increase from ¥69,164,061.26 in Q1 2023, reflecting a growth of approximately 57.7%[22] - The net cash flow from investing activities was -¥63,759,854.47, compared to -¥33,293,931.92 in the previous year, indicating a decline of about 91.1%[22] - The net cash flow from financing activities was -¥15,199,172.59, which is a decrease from -¥12,503,725.80 in Q1 2023, representing a decline of approximately 21.6%[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 7,186,668,564.94, reflecting a 2.77% increase from CNY 6,992,835,052.50 at the end of the previous year[5] - Current assets totaled CNY 3,521,007,668.76, up from CNY 3,399,871,398.68 at the start of the quarter, reflecting a growth of approximately 3.5%[15] - Total liabilities reached CNY 1,120,244,305.77, compared to CNY 1,046,909,543.49 at the beginning of the quarter, marking an increase of about 7%[15] - Total liabilities increased to ¥1,230,279,347.20, up from ¥1,162,789,279.07 year-on-year[19] - The total non-current assets amounted to CNY 3,665,660,896.18, up from CNY 3,592,963,653.82, reflecting an increase of approximately 2%[15] Research and Development - R&D expenses rose by 65.73%, amounting to an increase of CNY 27,170,900, primarily due to increased investment in research and development[8] - Research and development expenses rose to ¥68,506,786.98, a significant increase of 65.7% from ¥41,335,925.30 in Q1 2023[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 32,710[10] - Total equity attributable to shareholders reached ¥5,907,070,224.20, compared to ¥5,786,121,230.23 in the previous year[19] Other Income and Expenses - Other income increased by 206.7%, with an increase of CNY 3,812,100, mainly due to additional government subsidies received[8] - Operating costs amounted to ¥872,354,424.50, up 9.8% from ¥794,203,612.80 year-on-year[17] - Other comprehensive income after tax was negative at ¥-30,172,868.95, contrasting with a positive ¥14,438,696.65 in Q1 2023[19] Cash and Cash Equivalents - The company's cash and cash equivalents stood at CNY 1,667,358,088.81, slightly up from CNY 1,660,043,552.04, showing a marginal increase[14] - The total cash and cash equivalents at the end of Q1 2024 amounted to ¥1,644,145,718.81, down from ¥1,739,153,167.09 at the end of Q1 2023[22] Miscellaneous - The company reported a 100% increase in cash received from investment, totaling CNY 16,000,000, attributed to equity transfer payments received during the period[8] - The company experienced a 130.78% increase in contract liabilities, amounting to an increase of CNY 40,970,400, due to increased pre-receipts of sales[8] - The company did not undergo an audit for the Q1 2024 report[23] - The report was released by the chairman, Zhang Yusong, on April 25, 2024[23]